Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Truist lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $18 from $21 but keeps a Buy rating on the shares after its Q4 results ...

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's ...

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clin ...

ofatumumab and radioimmunotherapy). Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing of such ...

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s ...

New Bifunctional Chelators for Ac-225 and 227Th Radioimmunotherapy TAT-11: Various Chromatographic Schemes for Separation of 213Bi from Ac-2.25 TAT-11: Coordination Chemistry of +3 Actinium TAT-11: ...

225Ac-DOTA-YS5 radioimmunotherapy suppressed PSMA positive and deficient models, and FG-3246 is a novel antibody drug conjugate to CD46 in clinical trials (phase 1 with mCRPC with clinical activity).